



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s) Xianqiang Li

Serial No.: 09/877,705

Filed: June 8, 2001

Title: Method For Screening For Drug Candidates For  
Modulating Transcription Factor Activity

PATENT APPLICATION

Group: 1639

Examiner: T. D. Wessendorf

Confirmation No.: 1050

TECH CENTER 1600/2600

SEP 12 2003

RECEIVED

**TERMINAL DISCLAIMER TO OBVIATE A PROVISIONAL DOUBLE PATENTING REJECTION  
OVER A PENDING SECOND APPLICATION**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Panomics, Inc., the owner of 100% interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. 154 to 156 and 173, as presently shortened by any terminal disclaimer filed prior to the grant of any patent granted on commonly owned pending second Application No. 09/877,243, filed on June 8, 2001. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the second application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. 154 to 156 and 173 of any patent granted on the second application, as shortened by any terminal disclaimer filed prior to the patent grant, in the event that any such granted patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims canceled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer filed prior to its grant.

Check either box 1 or 2 below, if appropriate.

1. ☐ For submission on behalf of any organization (e.g., corporation, partnership, university, government agent, etc.), the undersigned is empowered to act on behalf of the organization.

I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

2. ☒ The undersigned is an attorney of record.

09/10/2003 EAREGAY1 00000113 232415 09877705

02 FC:2814

55.00 DA

Respectfully submitted,

WILSON SONSINI GOODRICH & ROSATI

Date: Sept. 8, 2003

Shirley Chen  
Shirley Chen, Reg. No. 44,608

650 Page Mill Road  
Palo Alto, CA 94304  
(650) 493-9300  
Customer No. 021971

- ☒ Charge Deposit Account 23-2415 the sum of \$55.00 for a small entity for the terminal disclaimer fee and for any fee deficiency.  
☐ PTO suggested wording for terminal disclaimer was:  
☒ unchanged ☐ changed (if changed, an explanation should be supplied). Explanation:

>\*Certification under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee.<